licensing agreement – Talk Bio

Actionable Insights Powered by AI

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

4 weeks ago talkbio0Tagged Adagene, Antibodies, Bispecific, Arc Bio, CD3 T cell, Clinical Trials, engagers, licensing agreement, lorigerlimab, MacroGenics, mCRPC, SAFEbody technology

MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals

Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal

5 months ago talkbio0Tagged Clinical Trials, Denali, Glaucoma, Kowa, licensing agreement, milestone payments, naproxen-n-butyl nitrate, Ophthalmology specialty, royalties, TLX2 gene

Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments

GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment

5 months ago talkbio0Tagged cabotegravir, Environmental pool, generic manufacturing, Global Health, HIV, licensing agreement, SmithKline Beecham, ViiV Healthcare

GSK; ViiV Healthcare; long-acting HIV treatment; cabotegravir; licensing agreement; Medicines Patent Pool; generic manufacturing; HIV; global health

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

6 months ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001

9 months ago talkbio0Tagged Alumis, Dermatology field, Dosage Forms, ESK-001, Inhibitor, Japan, Kaken, licensing agreement, TYK2 gene

Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan

Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal

9 months ago talkbio0Tagged Arteriosclerosis, Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, licensing agreement, Lp(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement

Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug

9 months ago talkbio0Tagged Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, Inhibitor, licensing agreement, Lipoprotein(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement

Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal

9 months ago talkbio0Tagged BDTX-4933, Black Populations, Diamond Therapeutics, licensing agreement, RAS/RAF inhibitor, Servier, Solid Neoplasm

Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor

AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes

9 months ago talkbio0Tagged Alteogen, AstraZeneca, Enzymes, Halozyme, hyaluronidase, Legal patent, licensing agreement, Merck, Subcutaneous Cancer

AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme

Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal

9 months ago talkbio0Tagged Dosage Forms, licensing agreement, Polycythemia, RNA-targeted medicine, Sapablursen, vera

Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine